Newcastle Confidence in Concept 2016
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
Publications
Becker KA
(2018)
Sphingolipids as targets for inhalation treatment of cystic fibrosis.
in Advanced drug delivery reviews
Hunt NC
(2018)
The Application of Biomaterials to Tissue Engineering Neural Retina and Retinal Pigment Epithelium.
in Advanced healthcare materials
Da Conceicao Ribeiro R
(2018)
Reactive jet impingement bioprinting of high cell density gels for bone microtissue fabrication.
in Biofabrication
Lumley HA
(2020)
A scoping review of pre-hospital technology to assist ambulance personnel with patient diagnosis or stratification during the emergency assessment of suspected stroke.
in BMC emergency medicine
Kandhari N
(2019)
Effects of dietary nitrate and folate supplementation on blood pressure in hypertensive Tanzanians: Design and baseline characteristics of a feasibility trial.
in Contemporary clinical trials communications
Price CI
(2020)
Asymmetrical Bioimpedance in the Anterior Circulation for Urgent Stratification of suspected Stroke (ABACUS Stroke): study protocol for a diagnostic accuracy study.
in Diagnostic and prognostic research
Shaw L
(2021)
Purines for Rapid Identification of Stroke Mimics (PRISM): study protocol for a diagnostic accuracy study.
in Diagnostic and prognostic research
Chichagova V
(2018)
Cellular regeneration strategies for macular degeneration: past, present and future.
in Eye (London, England)
Kamala O
(2021)
Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice.
in Frontiers in immunology
Delpiano L
(2018)
Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells.
in Frontiers in pharmacology
Description | The award was intended to provide preliminary data that would inform the preparation of applications for more substantial grant funding. The award proved extremely successful in this regard. Discoveries from the award led to substantial further funding in areas that included rare diseases (Newcastle now has a dedicated Centre for Rare Diseases), renal complement-related disease, stroke, retinal disease, and respiratory viral infection. |
Exploitation Route | The funding leveraged by the Confidence in Concept award has led to larger scale funding that will train researchers in the areas described above. It is highly likely that the work in each of the areas above will lead to further funding awards, with a translational focus. |
Sectors | Healthcare Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
Description | Work into rare diseases has contributed to the consolidation of Newcastle's expertise into a dedicated Centre for Rare Diseases, which is well placed to generate new funding in rare diseases, and to coordinate clinical trials into rare diseases. Work into retinal models has generated onward funding into regenerative medicine and the generation of high quality models of human eye disease. Work into respiratory viral infection included work that led to studies of COVID interaction with human upper airway epithelium, and also led to onward, substantial funding into the role of type I interferons in human respiratory epithelium. Work into renal ciliopathies fed into the Newcastle Centre for Rare Diseases, while work into renal complement-mediated disease led to substantial downstream funding, suggesting potential new therapeutic targets. |
First Year Of Impact | 2020 |
Sector | Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
Impact Types | Economic |
Description | A diagnostic accuracy study of portable EEG to triage acute stroke |
Amount | £221,623 (GBP) |
Organisation | Forest Devices (USA) |
Sector | Private |
Country | United States |
Start |
Description | AuToDeCRA 2 - Matching physiology to function: study autologous tolerogenic dendritic cell therapy focus on delivery route |
Amount | £1,106,921 (GBP) |
Funding ID | 21811 |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2018 |
End | 07/2022 |
Description | Confidence in Concept 2018 - New tools to image pulmonary embolism without exposure to ionising radiation |
Amount | £68,878 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2020 |
End | 02/2021 |
Description | Development of novel type I interferon inhibitors |
Amount | £10,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2021 |
Description | EPSRC Impact Accelerator Award |
Amount | £45,000 (GBP) |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Investigating the antimicrobial activity of sphingoid bases as a novel therapy against respiratory infection in children |
Amount | £181,792 (GBP) |
Funding ID | BH181815 |
Organisation | Newcastle upon Tyne Hospitals NHS Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2019 |
End | 02/2021 |
Description | Investigating the antimicrobial activity of sphingosine as a novel therapy against respiratory infection in children |
Amount | £181,792 (GBP) |
Organisation | Newcastle upon Tyne Hospitals NHS Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Investigation of replapsed Burkitt lymphoma |
Amount | £1,500 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Medimmune Grant |
Amount | £20,000 (GBP) |
Funding ID | 8300264934 |
Organisation | AstraZeneca |
Department | MedImmune |
Sector | Private |
Country | United Kingdom |
Start | 04/2017 |
End | 05/2022 |
Description | Microglia in the type I interferon system: protective and pathogenic mechanisms |
Amount | £412,853 (GBP) |
Funding ID | 211153 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2018 |
End | 11/2021 |
Description | PREMNEC: Preterm enteroids for determining the mechanism of necrotising enterocolitis |
Amount | £161,574 (GBP) |
Organisation | Marie Curie |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Personalised Therapies for all: Restoring airway function in CF using Alternative Chloride Channels |
Amount | £750,000 (GBP) |
Organisation | Cystic Fibrosis Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Precision medicine technologies: shaping the future - Point-of-care for stroke subtype diagnosis to enable rapid treatment |
Amount | £939,000 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | Process Control and Novel Materials for the Reactive Jet Impingement Process |
Amount | £1,145,056 (GBP) |
Funding ID | EP/V013092/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2024 |
Description | Purines for Rapid Identification of Stroke Mimics (PRISM) |
Amount | £711,974 (GBP) |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start |
Description | Sir Henry Dale Fellowship |
Amount | £995,985 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2020 |
Description | The role of tumour-infiltrating macrophages, dendritic cells, and T- regulatory cells in Classical Hodgkin lymphoma |
Amount | £9,261 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Type 1 interferon in Zika virus neuropathy |
Amount | £10,000 (GBP) |
Organisation | British Medical Association (BMA) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | Understanding the Properdin Paradox using C3 D1115N (gain-of-function) knock-in mice |
Amount | £569,241 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Wellcome Trust ISSF - The role of tumour-infiltrating macrophages, dendritic cells, and T- regulatory cells in Classical Hodgkin lymphoma |
Amount | £9,261 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start |
Description | i4i Innovative diagnostic test for early stage, high risk, melanoma AMLo |
Amount | £927,143 (GBP) |
Funding ID | II-LA-0417-20001 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 06/2018 |
End | 12/2020 |
Title | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF |
Description | Certain embodiments of the present invention relate to regulation of the innate immune system and complement activation. In particular, but not exclusively certain embodiments relate to a complement regulator protein and pharmaceutical compositions thereof for use in the treatment of diseases associated with or mediated by the alternative complement pathway and methods of treating such diseases and other subject matter. |
IP Reference | WO2018197873 |
Protection | Patent application published |
Year Protection Granted | 2018 |
Licensed | No |
Impact | It is hoped that this invention will make an impact in the field of kidney transplantation. |
Company Name | AMLo Biosciences |
Description | AMLo Biosciences develops a test for early stage cancer patients designed to determine the risk levels of the disease spreading. |
Year Established | 2017 |
Impact | The company is developing prognostic tests,to help healthcare providers identify which patients are most at risk of melanoma disease progression. |
Website | https://amlo-biosciences.com/ |